http://www.durviss.com/catalogue/entrance.html
Officials at the Seattle biopharmaceutical CTIC) said the company is now in compliancre with NASDAQCapital market’s minimum $35 milliohn market value requirement, as the result of an increase in the company’s share price. Previously, Cell Therapeutics was listed on NASDAQ’s Globaol market, which required a minimuj $50 million market value requirement. Cell Therapeuticxs then requested listing onthe exchange’xs Capital Market, which has the $35 million markey value requirement. Also, on March 23, NASDAQ extende d its suspension of the rules requirin g aminimum $1 closing bid price, at leasr through July 20, citing “continued extraordinary market conditions.
” That’a good news for Cell Therapeutics, which closed Fridayu at around 39 cents, up about 5 cents, or up more than 14 Shares in Cell Therapeutics haven’t traded above $1 since last
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment